"Cladribine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
| Descriptor ID |
D017338
|
| MeSH Number(s) |
D03.633.100.759.590.138.300.200 D03.633.100.759.590.138.325.075 D13.570.230.229.075 D13.570.583.138.300.200 D13.570.583.138.325.075 D13.570.800.096.300.200
|
| Concept/Terms |
Cladribine- Cladribine
- 2-Chlorodeoxyadenosine
- 2-Chloro-2'-deoxyadenosine
- 2'-Deoxy-2-chloroadenosine
|
Below are MeSH descriptors whose meaning is more general than "Cladribine".
Below are MeSH descriptors whose meaning is more specific than "Cladribine".
This graph shows the total number of publications written about "Cladribine" by people in this website by year, and whether "Cladribine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cladribine" by people in Profiles.
-
COVID-19 in Cladribine-treated patient with multiple sclerosis. J Neuroimmunol. 2021 10 15; 359:577690.
-
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine. Neurol Sci. 2021 Sep; 42(9):3533-3535.
-
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Mult Scler Relat Disord. 2021 Jul; 52:102983.
-
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update. Mult Scler Relat Disord. 2021 Jun; 51:102929.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? Mult Scler Relat Disord. 2021 04; 49:102775.
-
COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J Neurol. 2021 Aug; 268(8):2697-2699.
-
Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. J Immunoassay Immunochem. 2020 Nov 01; 41(6):960-975.
-
Normal antibody response after COVID-19 during treatment with cladribine. Mult Scler Relat Disord. 2020 Nov; 46:102476.
-
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Mult Scler Relat Disord. 2020 11; 46:102469.